<?xml version="1.0" encoding="UTF-8"?>
<p>On the other hand, we also found pathophysiological components of T2DM that could lead to PD such as metabolic inflammation [
 <xref rid="B31" ref-type="bibr">31</xref>], downregulation of dopamine in the nigrostriatal pathway [
 <xref rid="B32" ref-type="bibr">32</xref>–
 <xref rid="B34" ref-type="bibr">34</xref>], long-term hyperglycemia condition [
 <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/29890391" xmlns:xlink="http://www.w3.org/1999/xlink">35</ext-link>], decrease in the expression of 
 <italic>PGC-1α</italic> (peroxisome proliferator-activated receptor-gamma coactivator-1
 <italic>α</italic>) [
 <xref rid="B36" ref-type="bibr">36</xref>–
 <xref rid="B39" ref-type="bibr">39</xref>], increase in the expression of PED/PEA-15 (phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 protein) [
 <xref rid="B40" ref-type="bibr">40</xref>], increased methylglyoxal levels [
 <xref rid="B41" ref-type="bibr">41</xref>, 
 <xref rid="B42" ref-type="bibr">42</xref>], and the formation of alpha-synuclein amyloid fibrils [
 <xref rid="B17" ref-type="bibr">17</xref>].
</p>
